Table 2.
Prevalence of clinical indicators of advanced Parkinson's disease, by assigned disease severity groupa, b.
| Indicator | Overall (N = 144,703) |
Mild-Moderate PD (n = 115,729) |
Advanced PD (n = 28,974) |
|||
|---|---|---|---|---|---|---|
| N | Percent | N | Percent | N | Percent | |
| Any deep brain stimulationc | 3690 | 2.6% | 1880 | 1.6% | 1810 | 6.2% |
| Fall | 8099 | 5.6% | 6298 | 5.4% | 1801 | 6.2% |
| Hallucinations | 4724 | 3.3% | 3246 | 2.8% | 1478 | 5.1% |
| Walker | 7907 | 5.5% | 6250 | 5.4% | 1657 | 5.7% |
| Wheelchair | 12,784 | 8.8% | 9739 | 8.4% | 3045 | 10.5% |
| Specialty bed | 7711 | 5.3% | 5974 | 5.2% | 1737 | 6.0% |
| Dementia | 55,085 | 38.1% | 45,347 | 39.2% | 9738 | 33.6% |
| Skilled nursing facility | 374 | 0.3% | 267 | 0.2% | 107 | 0.4% |
| Hospice | 2545 | 1.8% | 1913 | 1.7% | 632 | 2.2% |
PD, Parkinson's disease.
a
Patients were classified based on an algorithm derived from prescription claims. Patients with any 30-day average levodopa equivalent dose (LED) >1000 mg/day were classified as advanced; all others were classified as mild-moderate.
b
Comparisons of patient subgroups for all variables listed were statistically significant at the P < 0.001 level.
c
Deep brain stimulation was defined as the presence of any CPT code indicating current or recent treatment (e.g., device placement or programming).